a public good project by the
Synthesis
Company
of California

© 2026

Isabel Figueroa | doi.page

0 works0 citations0 h-index

Isabel Figueroa

Amgen (United States)(US)Gilead Sciences (United States)(US)Instituto Politécnico Nacional(MX)

Publications by Year

Research Areas

Monoclonal and Polyclonal Antibodies Research, HER2/EGFR in Cancer Research, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors

Most-Cited Works

→ Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity(2019)185 cited
→ Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin(2012)145 cited
→ Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug Conjugates(2016)139 cited
→ Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells(2018)57 cited
→ Development of a therapeutic anti-HtrA1 antibody and the identification of DKK3 as a pharmacodynamic biomarker in geographic atrophy(2020)55 cited
→ Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection(2015)36 cited

→ A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins(2019)

31 cited

→ Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody–Drug Conjugates(2018)23 cited

→ Front Cover: Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity (ChemMedChem 1/2020)(2020)22 cited

→ Tissue Physiology of Cynomolgus Monkeys: Cross-Species Comparison and Implications for Translational Pharmacology(2018)21 cited